Hisco announced that the company recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. The clinical trial application for HSK51155 tablets accepted in May 2026 met the relevant requirements for drug registration and agreed to carry out clinical trials with this product. HSK51155 is an oral small molecule analgesic drug independently developed by the company. It is intended to be used for migraine treatment. In April 2026, the company reached a cooperation agreement with AbbVie on this project, and the total potential transaction amount exceeds 700 million US dollars.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.